Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. (Q38014531)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Samit Patrawala

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

509-523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

Targeting the mitogen-activated protein kinase cascade to treat cancer

2 February 2020

cites work

1 reference

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

21 January 2018

1 reference

Detection of B-RAF and N-RAS mutations in human melanoma

21 January 2018

1 reference

Analysis of BRAF mutation in primary and metastatic melanoma.

21 January 2018

1 reference

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Recurrent BRAF mutations in Langerhans cell histiocytosis

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

21 January 2018

1 reference

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.12.31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22646766%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference